Clinical Trial Update: Lanreotide In Polycystic Kidney Disease Study [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating lanreotide for autosomal dominant polycystic kidney disease (ADPKD) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• Lanreotide (lanreotide)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD | Phase 3 | Status: COMPLETED